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DObjective: One of the hemodynamic consequences of aortic valve stenosis is pressure overload leading to left
atrial dilatation. Left atrial size is a known risk factor providing prognostic information in several cardiac con-
ditions. It is not known if this is also the case in patients with aortic valve stenosis after aortic valve replacement.
Methods: A total of 119 patients with severe aortic valve stenosis scheduled for aortic valve replacement were
evaluated preoperatively and divided into 2 groups according to left atrial volume index (40 mL/m2). Echo-
cardiography was repeated 12 months after surgery. Patients were followed up for 24 months. The primary
end point was the composite end point overall mortality and hospitalization due to congestive heart failure.
Results: Preoperative left atrial dilation was associated with left ventricular hypertrophy and increased filling
pressure. Preoperative left atrial volume index was associated with persistent abnormalities in left ventricular
filling pressure and left ventricular mass index at 1 year after surgery. Event-free survival in patients with left
atrial volume index of 40 mL/m2 or more at 1 year was 71% compared with 88% in patients with left atrial
volume index less than 40 mL/m2 (P¼ .002). Patients with preoperative increased E/e’ ratio and left ventricular
hypertrophy were at increased risk. In Cox regression analysis after correcting for standard risk factors, left atrial
volume index was found to be the only significant predictor of the composite end point. In a forward conditional
multivariable model, left atrial volume index 40 mL/m2 or greater (hazard ratio, 4.2 [1.6–10.7]; P ¼ .003)
remained an independent predictor, whereas E/e’ was borderline significant (P ¼ .06).
Conclusions: In patients with symptomatic severe aortic valve stenosis undergoing aortic valve replacement,
left atrial volume provides important prognostic information beyond standard risk factors. (J Thorac Cardiovasc
Surg 2011;142:e77-83)AAortic stenosis (AS) is characterized by left ventricular
(LV) pressure overload that will lead to increased filling
pressure and increased wall stress, which is further aug-
mented by LV hypertrophy and fibrosis. Thus, LV pressure
overload will cause left atrial (LA) pressure overload and
eventually provoke symptoms resulting from a predominant
LV diastolic dysfunction. When symptoms are present, aor-
tic valve replacement (AVR) is recommended. However,
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The Journal of Thoracic and Cahypertrophy is often found even after several years,1-3
leaving a permanent substrate for increased mortality and
morbidity.4-6 Several studies have clearly shown that
elevated filling pressures7 and diastolic dysfunction8 are
common late after surgery, and it has thus been proposed
that AVR should be recommended before irreversible
remodeling is present.7,9 In addition, a previous study
demonstrated that elevated pulmonary capillary wedge
pressure before valve replacement identified patients with
abnormal exercise hemodynamics after surgery.7 However,
traditional monitoring of patients with aortic valve stenosis
is echocardiographic assessment of aorta valve area and
evaluation of symptomatic status. During conventional
echocardiography, noninvasive estimation of filling
pressure based on the ratio of early diastolic mitral inflow
velocity to early diastolic mitral annular velocity (E/e’)
and LA volume is commonly performed. Little is known
of the importance of noninvasive estimation of filling pres-
sure for remodeling and outcome after AVR. Thus, the pres-
ent study evaluates the importance of severe LA dilatation
and increased filling pressure estimated noninvasively for
reverse remodeling, morbidity, and mortality in patients
with symptomatic AS undergoing AVR.rdiovascular Surgery c Volume 142, Number 3 e77
Abbreviations and Acronyms
AS ¼ aortic stenosis
ASE ¼ American Society of
Echocardiography
AVR ¼ aortic valve replacement
LA ¼ left atrial
LAVi ¼ left atrial volume index
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
NT-proBNP ¼ N-terminal pro-brain natriuretic
peptide
RWT ¼ relative wall thickness
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DMATERIALS AND METHODS
The present study is a prespecified substudy of a prospective single-
center, randomized study to evaluate the effect of candesartan compared
with conventional treatment on reverse remodeling in consecutive patients
undergoing AVR for symptomatic aortic valve stenosis. The study was reg-
istered with the National Board of Health and the Danish Data Protection
Agency, and approved by the local ethical committee. All patients gave
written informed consent.
Screening and Inclusion
Eligible patients were aged more than 18 years, had symptomatic severe
AS (estimated aortic valve area<1 cm2), and underwent AVR at Odense
University Hospital between February 2006 and April 2008. Patients
with LV systolic dysfunction (LV ejection fraction [LVEF]<40%), renal
failure (S-creatinine>220 mmol/L), previous aortic valve surgery, planned
additional valve repair/replacement, acute infective endocarditis, pre-
dominantly aortic valve regurgitation, and ongoing treatment with an
angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
were excluded. The need for AVR was decided by consensus among senior
cardiologists, cardiac surgeons, and anesthetists not involved in the present
study. Of the 232 patients screened for participation, 49 refused participa-
tion in the study, 59 met at least 1 exclusion criteria, and 5 did not undergo
surgery, leaving 119 patients in the study.
Echocardiography
All echocardiograms were performed by the same operator on a GE
Vivid 5 ultrasound machine (GE Medical System, Horten, Norway) the
day before surgery. Echocardiography was repeated 12 months after sur-
gery in 99 patients; 17 patients died during follow-up and 3 patients with-
drew consent. Operators who examined all measurements were blinded to
the preoperative results.
Aortic valve area was estimated using quantitative Doppler using the
continuity equation. The diameter of the LV outflow tract was measured
from a zoomed image of the LV outflow tract obtained in the parasternal
long-axis view. Peak flow velocity across the valve was determined in
the apical window or the echocardiographic window where the highest
peak velocity could be obtained by placing the continuous-wave Doppler
cursor as parallel as possible with the flow across the valve. Peak transvalv-
ular gradient was estimated using the simplified Bernoulli equation. Fi-
nally, the peak systolic flow velocity in the outflow tract was estimated
with pulsed-wave Doppler.
LV mass was estimated according to the joint recommendations of the
American Society of Echocardiography (ASE) and European Association
of Echocardiography using Devereux’s formula for ASE measurements
in diastole: 0.8 3 (1.04 3 ([LV internal dimension þ posterior walle78 The Journal of Thoracic and Cardiovascular Surgthicknessþ interventricular septal thickness]3 – [LV internal dimension]3)
þ0.6 g.10 LV wall thickness and dimensions were estimated from the aver-
age of 3 consecutive 2-dimensional images obtained in the parasternal
long-axis view according to guidelines. LV mass index greater than 116
g/m2 in men and greater than 100 g/m2 in women were considered indica-
tive of LV hypertrophy. Relative wall thickness (RWT) was calculated for
assessment of LV geometry using the formula 23 posterior wall thickness/
LV diastolic diameter. Increased RWT was present when this ratio was
greater than 0.42.10 Normal geometry was present when LV mass index
and RWTwere normal, whereas increased RWTand normal LVmass index
identified concentric remodeling. Increased LV mass index but normal
RWT identified the eccentric LV hypertrophy, whereas increases in both
variables identified concentric LV hypertrophy.10
LA volume was measured in LV end systole in the frame preceding
mitral valve opening. The volume was measured using the biplane area
length method and corrected for body surface area. Patients were consid-
ered to have severe LA dilatation if left atrial volume index (LAVi) was
40 mL/m2 or greater.10 On the basis of the presence of severe LA dilatation
preoperatively, patients were divided into 2 groups. The absolute
interobserver agreement on LA volume index greater than or less than
40 mL/m2 between 2 observers was obtained in 20 randomly selected
patients. Agreement was substantial: 90%, kappa 0.80.
LVEFwasestimatedusingSimpson’s biplanemethod.Mitral regurgitation
was quantified as none, mild, moderate, or severe using standard methods.11
Mitral inflow was assessed in the apical 4-chamber view using pulsed-
wave Doppler with the sample volume placed at the tips of mitral leaflets
during diastole. From the mitral inflow profile, the E- and A-wave peak ve-
locities and deceleration time were measured. Doppler tissue imaging of
the mitral annulus was obtained from the apical 4-chamber, 2-chamber,
and long-axis views, using a sample volume placed in the septal, lateral,
anterior, inferior, and posterior mitral valve annuli. The e’ velocity from
each site and themean valuewere determined, and the respective E/e’ ratios
were derived. According to the 2009 ASE guidelines,12 patients with an
E/e’septal greater than 15, E/e’ lateral greater than 12, or E/e’ mean greater
than 13were considered to have increased filling pressure, whereas patients
with E/e’septal, E/e’ lateral, or E/e’ mean less than 8 were considered to have
normal filling pressure. In the remaining patients with an indeterminate
E/e’ ratio, those with LAVi 34 mL/m2 or greater were considered to have
increased filling pressure and those with LAVi less than 34 mL/m2 were
considered to have normal filling pressure.12Plasma N-Terminal Pro-Brain Natriuretic Peptide
Blood samples were collected immediately after the echocardiogram,
after the subject had been resting recumbent for at least 30 minutes. Sam-
ples were collected in EDTA tubes. These were then centrifuged, and
plasma samples were stored at80C for later analysis. N-terminal pro-
brain natriuretic peptide (NT-proBNP) was determined using an ELECSYS
proBNP immunoassay (Roche Diagnostics GmbH, Mannheim, Germany).
Clinical Follow-up
A clinical examination assessing symptoms and signs of heart failure
was performed before surgery and repeated 12 months after AVR (median,
12.2 months; range, 11.6–14.6 months). Assessment of New York Heart
Association class was performed before echocardiography in all cases. In
addition, a 6-minute walk test was performed before surgery and at 12
months postoperatively. All 119 patients were followed until June 2009,
and all hospitalizations and deaths were recorded. The main end point
for this study was the composite end point of overall mortality and hospi-
talization due to worsening heart failure.
Statistics
Data are presented as mean  standard deviation or number and per-
centages. Differences between groups were tested by Student t tests forery c September 2011
Dahl et al Acquired Cardiovascular Diseaseunpaired data once normality was demonstrated, and categoric variables
were tested by the Fisher exact test. Because of a non-Gaussian distribu-
tion, NT-proBNP was logarithm transformed. Mortality and event rates
were calculated using the product limit method and plotted according to
the Kaplan–Meier method. Death rates were compared using the log-
rank test. Further estimation of risk was performed using Cox proportional
hazard models. Because of colinearity, LAvolume index, E/e’ ratio, and LV
mass index were tested in separate models after adjustment for known pre-
dictors as age, gender, euroSCORE, logNT-proBNP, and concomitant
CABG surgery. The assumptions (proportional hazard assumption, linear-
ity of continuous variables, and lack of interaction) were tested and found
valid. STATA/SE 9.0 (StataCorp LP, College Station, Tex) software was
used for statistical analysis.TABLE 2. Preoperative echocardiographic data
LAVi<40
mL/m2
n ¼ 43
LAVi  40
mL/m2
n ¼ 76
P
value
AVA (cm2) 0.84  0.23 0.80  0.30 .40
LVEF (%) 55  7 53  8 .19
LVEF<45% 1 (2%) 10 (13%) .06
LVEDV (mL) 101  28 116  36 .021
LV end-diastolic diameter 4.3  0.6 4.6  0.6 .038RESULTS
The mean LAVi at baseline was 49.7  18.4 mL/m2, and
LAVi exceeded 40 mL/m2 in 76 patients (64%). Clinical
and operative characteristics of the population are shown
in Table 1. Patients with severe LA dilatation were older
(75 9 years vs 69 10 years, P¼ .0005), had higher pre-
operative euroSCORE, and were more likely to have atrial
fibrillation at baseline (2% vs 21%, P ¼ .005). Heart fail-
ure class was identical in both groups (New York Heart As-
sociation class 2.1  0.7 vs 2.1  0.7, P ¼ .73), and
although there was a trend toward poorer performance on
the 6-minute walk test in patients with increased LA vol-
ume, this difference was not statistically significant:
P ¼ .2 (Table 1).TABLE 1. Patient characteristics
LAVi<40
mL/m2
n ¼ 43
LAVi  40
mL/m2
n ¼ 76
P
value
Age, y 69  10 75  9 .0005
Male gender 30 (70%) 44 (58%) .24
Hypertension 14 (33%) 34 (48%) .24
Diabetes 9 (21%) 10 (13%) .31
Atrial fibrillation 1 (2%) 16 (21%) .005
Coronary heart disease 8 (19%) 13 (17%) 1.00
Peripheral artery disease 4 (9%) 7 (9%) 1.00
Stroke 4 (9%) 4 (5%) .46
Diuretic therapy 12 (28%) 31 (41%) .17
b-blocker therapy 10 (23%) 17 (22%) 1.00
CCB therapy 10 (23%) 14 (18%) .64
Symptoms
6-min walk test (m) 359  121 325  125 .20
NYHA 2.1  0.7 2.1  0.7 .73
NYHA 3–4 12 (28%) 23 (30%) .84
Chest pain 27 (63%) 32 (42%) .04
euroSCORE 5.2  1.9 6.2  2.0 .015
Logistic euroSCORE 4.5  3.3 6.3  4.4 .02
CABG 13 (30%) 24 (32%) 1.0
Mechanical prosthesis 12 (28%) 7 (9%) .009
Valve size (mm) 23.6  4.2 22.7  4.2 .24
Maze surgery 0 (0%) 10 (13%) .01
LAVi, Left atrial volume index; CCB, calcium channel blocker; CABG, Coronary ar-
tery bypass grafting; NYHA, New York Heart Association.
The Journal of Thoracic and CaPreoperative Left Ventricular Structure and
Function
Severe LA dilatation was associated with increased
LVMi and higher NT-proBNP, and severe LA dilatation
was associated with presence of concentric hypertrophy
(Table 2). In addition, both LVend-diastolic volume and di-
ameter were significantly increased in patients with severe
LA dilatation. Although preoperative LVEF was similar in
both groups (55 7 vs 53 8, P¼ .2), longitudinal LV sys-
tolic peak velocity of mitral annular motion (S’) was signif-
icantly lower in patients with severe LA dilation (Table 2).
Patients with a larger left atrium were more likely to have
a diastolic restrictive pattern (1 [3%] vs 22 [29%],
P ¼ .001) as defined by deceleration time less than 140
ms and E-wave to A-wave ratio greater than 1.5. No differ-
ence in moderate mitral regurgitation was seen in patients
with a larger left atrium (0% vs 5% P ¼ .30).LVMi (g/m2) 112  28 144  42 <.0001
RWT 0.60  0.12 0.60  0.15 .97
LVH geometry <.001
Normal 1 (2%) 3 (4%)
Concentric 26 (60%) 13 (17%)
Eccentric hypertrophy 1 (2%) 5 (7%)
Concentric hypertrophy 15 (35%) 55 (72%)
LAVi (mL/m2) 33  5 60  15 <.0001
E (ms) 0.69  0.18 0.87  0.23 <.0001
A (ms) 0.94  0.21 0.98  0.30 .44
E/A 0.77  0.25 0.97  0.59 .033
E’sept (cm/s) 5.9  1.3 5.5  1.6 .14
E’lat (cm/s) 7.2  2.1 7.3  2.6 .83
E’mean 2 segments (cm/s) 6.6  1.5 6.4  1.9 .62
DT (ms) 211  49 193  65 .11
Diastolic restrictive pattern 1 (3%) 22 (29%) .001
E/e’sept 11.9  3.0 16.9  5.6 <.0001
E/e’lat 10.1  3.4 13.3  5.7 .0012
E/e’mean 10.8  3.0 14.6  5.0 <.0001
High filling pressures 21 (49%) 64 (84%) <.001
S’mean (cm/s) 6.8  1.1 6.2  1.4 <.0001
NT-proBNP (median
interquartile range)
208 (123–335) 838 (361–1741) <.0001
logNT-proBNP 5.4  1.1 6.7  1.2 <.0001
creatinine 105  23 98  21 .10
Moderate mitral regurgitation 0 (0%) 4 (5%) .30
AVA, Aortic valve area; DT, deceleration time; LAVi, left atrial volume index; LVEF,
left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVH,
left ventricular hypertrophy; LVMi, left ventricular mass index; RWT, relative wall
thickness; NT-proBNP, N-terminal pro-brain natriuretic peptide.
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Although LVMi decreased significantly during follow-
up, the association with preoperative LAVi remained signif-
icant after 12 months (Table 3). LV hypertrophy was more
frequent after 1 year in the group with a large left atrium de-
spite reverse remodeling, and LV geometry remained ab-
normal in most patients (Table 3). RWT was not
significantly different between groups (0.55  0.13 vs
0.54  0.10, P ¼ .5). Although no difference in LVEF
was found between groups after 12 months (Table 3), the
proportion of patients with an ejection fraction less than
45%was significantly lower in the group with LA dilatation
(5% vs 25%, P¼ .02). In addition, longitudinal systolic ve-
locity, s’, remained significantly lower in patients with pre-
operatively LAVi 40 mL/m2 or more than in those with
LAVi less than 40 mL/m2 (7.1  1.4 cm/s vs 8.0  1.6
cm/s, P ¼ .009). Patients with severe LA dilatation wereTABLE 3. Results 12 months after aortic valve replacement,
according to preoperative left atrial volume index
LAVi<40
mL/m2
n ¼ 38
LAVi  40
mL/m2
n ¼ 61 P
LVMi (g/m2) 95  24 120  31 .0001
LV hypertrophy 11 (29%) 35 (57%) .007
RWT 0.55  0.13 0.54  0.10 .51
LV geometry .016
Normal 3 (8%) 7 (11%)
Concentric 24 (63%) 19 (31%)
Eccentric hypertrophy 1 (3%) 4 (7%)
Concentric hypertrophy 10 (26%) 31 (51%)
LAVi (mL/m2) 35  8 54  16 <.0001
LVEF 53  5 52  9 .77
LVEF<45% 2 (5%) 15 (25%) .024
S’mean (cm/s) 8.0  1.6 7.1  1.4 .0088
E/e’sept (cm/s) 12.9  5.3 17.5  7.9 .003
E/e’lat (cm/s) 8.6  2.9 11.8  5.3 .0014
E/e’mean (cm/s) 10.2  3.4 13.8  5.5 .0007
High filling pressures 18 (47%) 47 (77%) .004
Diastolic restrictive pattern 5 (17%) 17 (29%) .033
logNT-proBNP 5,4  0.9 6.3  1.1 <.0001
Moderate mitral regurgitation 0 (0%) 0 (0%) 1.00
Symptoms
NYHA 1.1  0.3 1.2  0.5 .71
NYHA 3–4 0 (0%) 2 (3%) .52
6-min walk (m) 425  93 404  113 .41
Difference during follow-up
–LVMi (g/m2) 19  26 23  40 .64
–LAVi (mL/m2) 2.7  8.0 4.9  14.0 .0034
–E/e’mean 0.4  3.7 0.5  5.8 .96
–S’mean (cm/s) 1.2  1.4 1.2  1.4 .98
–RWT 0.04  0.10 0.05  0.16 .71
NYHA, New York Heart Association; LAVi, left atrial volume index; LVEF, left
ventricular ejection fraction; LVMi, left ventricular mass index; RWT, relative wall
thickness.
e80 The Journal of Thoracic and Cardiovascular Surgmore likely to have a LV diastolic restrictive filling pattern
(17 [29%] vs 5 [17%], P ¼ .03).
After 12 months, E/e’ suggested increased filling pres-
sure in 65 patients (66%). This was most frequently seen
in patients with most severe preoperative LA dilatation
(47 [77%] vs 18 [47%], P¼ .004). In addition, significantly
higher E/e’sep (12.9  5.3 vs 17.5  7.9, P ¼ .003) and
logNT-proBNP (5.4 0.9 vs 6.3 1.1, P<.0001) were ob-
served among patients with LA dilatation preoperatively.
Postoperative Outcome
During a median follow-up of 24 months, 17 patients died
(n¼ 7 [postoperative during hospitalization], n¼ 9 [cardiac
death], n ¼ 1 [noncardiac death]) and 18 patients were hos-
pitalized for heart failure. Patients who died had signifi-
cantly increased preoperative LAVi compared with
survivors (60  18 mL/m2 vs 48  18 mL/m2, P ¼ .015).
One-year mortality rate in patients with LAVi 40 mL/m2 or
greater was 13% compared with 5% in patients with LAVi
less than 40 mL/m2, log-rank P ¼ .02 (Figure 1). Event-
free survival in patients with LAVi 40 mL/m2 or greater at
1 year was 71% compared with 88% in patients with pa-
tients with LAVi less than 40 mL/m2, P ¼ .002 (Figure 1).
Patients with preoperative increasedE/e’ ratio andLVhyper-
trophy were at increased risk (Figures 1 and 2). In
univariable Cox regression analysis, LVMi, LAVi, E/e’,
NT-proBNP, history of atrial fibrillation, and concomitant
CABG surgery were found to be predictors of the composite
end point (Table 4). After adjustment for age, euroSCORE,
logNT-proBNP, and concomitant CABG surgery, only LAVi
remained a predictor of the composite end point, although
there was a trend toward LVMi and E/e’ also being predic-
tive. On comparison of the overall log likelihood chi-
square of the predictive power of the multivariable model,
a model containing LAVi or E/e’ was statistically superior
to a model based on clinical variables or clinical variables
and LVMi. In a forward conditional multivariable model in-
cluding the aforementioned variables, LAVi 40 mL/m2 or
greater was the sole independent predictor HR 4.2 (95%
confidence interval, 1.6–10.7),P¼ .003. E/e’was borderline
predictive in this model (P ¼ .06) (data not shown).
DISCUSSION
The present study showed that preoperative LA dilatation
is associated with LV hypertrophy and increased filling
pressure in patients with severe aortic valve stenosis and
preserved LV systolic function. Moreover, preoperative
LA volume was associated with persistent abnormalities
in LV filling pressure and LV mass index at 1 year after sur-
gery, and LA dilatation was an independent predictor of
death or readmission.
During diastole, the left atrium is directly exposed to LV
pressure through the open mitral valve; thus, with increased
filling pressure the left atrium will dilate and can, in theery c September 2011
FIGURE 1. Kaplan-Meier plot showing overall survival, based on (A) preoperative left atrial volume index and (B) diastolic E/e’ ratio. Numbers represent
numbers at risk.
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considered a morphologic indicator of chronic LA pressure
overload.
Dalsgaard and colleagues13 recently demonstrated in the
Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study
that LV hypertrophy and diastolic dysfunction also are
closely associated with LA volume. The present study con-
firms and extends these observations, because we found that
preoperative severe LA dilatation remained associated with
increased postoperative filling pressures and severity of LV
hypertrophy, with these abnormalities persisting at 1 year of
follow-up. These findings are in accordance with a previous
study by Monrad and colleagues7 showing that severity of
LV hypertrophy and of elevated filling pressures before sur-
gery were predictive of elevated filling pressures after AVR,
indicating that some of the LV structural changes occurring
before surgery are irreversible and do not improve with
valve replacement.FIGURE 2. Kaplan-Meier plot showing survival from composite end-point, ba
Numbers represent numbers at risk.
The Journal of Thoracic and CaIn addition, we demonstrated that longitudinal systolic
function was depressed in patients with LAVi 40 mL/m2 or
greater despite preserved LVEF. In addition, systolic and di-
astolic function did not fully recover during follow-up, and
postoperative systolic dysfunction (LVEF<45%) occurred
more frequently in patients with severe LA dilatation. These
data suggest that a severely dilated left atrium identifies
patients at increased risk of irreversible LV remodeling.
In the present study, preoperative severity of LV hyper-
trophy, LAvolume, and diastolic E/e’- ratio were predictors
of outcome. These parameters provided information incre-
mental to well-established clinical risk factors.14 In
addition, both LAVi and E/e’ were incremental to LVMi,
indicating that the consequence of LV remodeling (ie,
increased filling pressure) is of prognostic importance. LV
hypertrophy, however, is only part of the structural changes
involving the LV in chronic pressure overload. The presence
of myocardial fibrosis has been suggested to precedesed on (A) preoperative left atrial volume index and (B) diastolic E/e’ ratio.
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TABLE 4. Univariable and multivariable predictors of composite end point
Univariable Multivariable*
Variable HR 95% CI P value HR 95% CI P value
Age (y) 1.03 0.99–1.08 .10
Gender 0.61 0.31–1.19 .15
euroSCORE 1.09 0.92–1.28 .29
CABG surgery 0.42 0.17–1.00 .050
LAVi  40 mL/m2 4.01 1.56–10.36 .004 3.07 1.11–8.51 .031
LAVi mL/m2 1.02 1.01–1.04 .002
E/e’average 1.09 1.03–1.16 .005 1.08 1.08–1.17 .09
LVMi 1.01 1.00–1.02 .001 1.01 1.00–1.02 .10
S’ 0.83 0.66–1.05 .12 0.98 0.73–1.31 .89
RWT 2.93 0.24–35.7 .40
LVEF 4.96 0.05–457 .49
Log-proBNP 1.35 1.06–1.74 .017
Known atrial fibrillation 2.20 1.03–4.68 .041
Moderate mitral regurgitation 0.75 0.10–5.50 .78
Candesartan treatment 0.90 0.47–1.75 .76
HR, Hazard ratio; CI, confidence interval; CABG, coronary artery bypass grafting; LAVi, left atrial volume index; RWT, relative wall thickness; LVEF, left ventricular ejection
fraction; LVMi, left ventricular mass index. Presented multivariable hazard ratios (*) for LAVi, E/e’average, LVMi, and S’ are calculated in 4 separate Cox proportional hazard
models with adjustment for age, gender, euroSCORE, concomitant CABG surgery, and log-proBNP.
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Ddevelopment LV hypertrophy in patients with hyperten-
sion15 and is often present in patients with aortic valve ste-
nosis.16 Several studies1,17,18 have shown that as
hypertrophy regresses postoperatively, fibrosis will
increase with consequently reduced LV compliance and
increased LV filling pressures. Because LAVi reflects the
physiologic effects of both LV hypertrophy and fibrosis,
this could explain the additive prognostic importance.
Increased mortality and morbidity predicted by preoper-
ative LA volume index are well documented in the general
population19 and in patients with ischemic heart disease20
and heart failure.21 To our knowledge, no studies have dem-
onstrated that this also applies for patients with aortic valve
stenosis undergoing valve replacement.
The presence of poorer postoperative LV function, in-
creased filling pressures, and increased mortality/morbidity
associated with increased preoperative LAVi suggests that
surgery should be considered before severe LA dilatation
has occurred. The benefit of anticipated surgery was dem-
onstrated in a study with 622 asymptomatic patients with
AS, in whom AVR improved survival even in patients
who remained asymptomatic.22 Larger studies should ad-
dress whether ideal timing of surgery should depend not
only on symptomatic status but also on morphologic indica-
tors of LV function to prevent the myocardium from under-
going irreversible damage.8,23,24
Study Limitations
The sample size was small, with few events; thus, our in-
ability to detect LVMi as a predictor in the multivariate
analysis may be a result of a type II error, and larger studies
are warranted.e82 The Journal of Thoracic and Cardiovascular SurgThe entry criterion for the study was symptomatic AS re-
ferred for AVR. Because of selection bias, it may reduce the
applicability to asymptomatic patients. Future studies
should be performed on asymptomatic patients to clarify
whether LAVi applies to a general population with AS.
LV structure was assessed by echocardiography, and no
histologic examinations were performed; thus, we can
only speculate that fibrosis accounts for the lack of improve-
ment in diastolic function.
LA dilatation may be secondary to volume overload,
most commonly mitral regurgitation. Patients with moder-
ate to severe mitral regurgitation were excluded from the
study, and few patients had more than mild mitral regurgi-
tation. Thus, we do not believe that mitral regurgitation is
an important confounder in the present study.
No direct hemodynamic measurements of LV end-
diastolic or LA pressure were performed. Although E/e’ is
accepted as a well-validated surrogate in a wide range of pa-
tients with cardiac disease,25 recent data have shown some
limitations of this parameter in patients with decompen-
sated LV systolic heart failure26 and during exercise in pa-
tients with aortic valve stenosis.27 Caution is thus required
in interpreting our E/e’ data as a parameter reflecting true
intracardiac filling pressures, especially because e’ may
be affected by cardiac surgery per se.
CONCLUSIONS
In patients with symptomatic severe AS undergoing AVR,
noninvasive assessment of filling pressures (E/e’ ratio and
LA volume index) provides important prognostic informa-
tion beyond standard risk factors. Furthermore, LAVi is asso-
ciated with postoperative LV systolic and diastolic function.ery c September 2011
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